Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Long-Term Investments (2023 - 2025)

Ascentage Pharma Group International posted quarterly Long-Term Investments of $4.7 million for Q4 2025, up 2.25% year-on-year from $4.6 million in Q4 2024, and up 1.97% on a QoQ basis from $4.6 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Long-Term Investments data on file, last reported at $4.7 million in Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments rose 2.25% year-over-year to $4.7 million; the trailing twelve-month figure through Dec 2025 stood at $4.7 million (up 2.25% YoY), and the FY2025 full-year result was $4.7 million, up 5.38% from the prior year.
  • Long-Term Investments for Q4 2025 stood at $4.7 million, up from $4.6 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $4.7 million in Q4 2025 and bottomed at $2.4 million in Q4 2023.
  • The 3-year median for Long-Term Investments is $4.6 million (2024), against an average of $4.0 million.
  • The widest annual swing landed in 2024, when Long-Term Investments soared 92.93%; it then grew 2.25% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $2.4 million in 2023, then jumped by 92.93% to $4.6 million in 2024, then rose by 2.25% to $4.7 million in 2025.
  • The last three Long-Term Investments figures came in at $4.7 million (Q4 2025), $4.6 million (Q2 2025), and $4.6 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 505,194.89
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 5.75 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 9.79 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 22.17 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 4.66 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 4.66 Mn
Jun 30, 2025 4.57 Mn
Dec 31, 2024 4.55 Mn
Dec 31, 2023 2.36 Mn